Education
About Us
Working with TipRanks
Follow Us
National Graphite Corp (NGRC)
:NGRC
NGRC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.02 - $0.08
Previous CloseN/A
Volume600.00
Average Volume (3M)34.00
Market Cap
$6.25M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-1.46
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding154,308,000
10 Day Avg. Volume74
30 Day Avg. Volume34
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
NGRC FAQ
What was National Graphite Corp’s price range in the past 12 months?
National Graphite Corp lowest stock price was $0.02 and its highest was $0.08 in the past 12 months.
What is National Graphite Corp’s market cap?
National Graphite Corp’s market cap is $6.25M.
When is National Graphite Corp’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were National Graphite Corp’s earnings last quarter?
Currently, no data Available
Is National Graphite Corp overvalued?
According to Wall Street analysts National Graphite Corp’s price is currently Overvalued.
Does National Graphite Corp pay dividends?
National Graphite Corp does not currently pay dividends.
What is National Graphite Corp’s EPS estimate?
National Graphite Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does National Graphite Corp have?
National Graphite Corp has 154,308,000 shares outstanding.
What happened to National Graphite Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of National Graphite Corp?
Currently, no hedge funds are holding shares in NGRC
Company Description
National Graphite Corp
National Graphite Corp., through its subsidiary, Biotech Development Corp., operates as a biopharmaceutical risk/cost-sharing company. The company collaborates with clinical stage companies that develop new biological entities or new therapeutically platforms for the treatment of various diseases, rare diseases, and diseases with unmet needs. It is developing a drug candidate called ELAFIN, which is a human identic protein for the treatment of postoperative inflammatory complications. National Graphite Corp. has a collaboration agreement with Proteo Inc. for developing ELAFIN. The company was formerly known as Lucky Boy Silver Corporation and changed its name to National Graphite Corp. in May 2012. National Graphite Corp. was founded in 2006 and is based in Duesseldorf, Germany.
Technical Analysis
Bolt Projects Holdings
―
―
―
Distoken Acquisition Corporation
―
Quetta Acquisition Corp.
―